Volume-led Revenue Growth
Total revenues increased 10% to $10.1B, driven by 9% product volume growth, with standout performances from Repatha (+37%), EVENITY (+38%), UPLIZNA (+90%), and IMDELLTRA (+115%).
At the archive date, AMGEN INC was expected to release its Q3 2026 10-Q filing on November 2, 2026, after market close. Last quarter: Amgen's Q2 FY2026 revenue grew 10% to $10.1B and net income surged 66% to $2.4B, driven by volume and lower amortization, while biosimilar and IRA headwinds intensified on mature brands.
EPS Estimate
$5.91
Revenue Estimate
$10.26B
Analyst consensus captured from Finnhub and Financial Modeling Prep. This archived preview is no longer updated with later results; see the AMGN page for retained reports.
Drawn from management commentary in the Q2 2026 10-Q:
Total revenues increased 10% to $10.1B, driven by 9% product volume growth, with standout performances from Repatha (+37%), EVENITY (+38%), UPLIZNA (+90%), and IMDELLTRA (+115%).
Cost of sales as a percentage of total revenues decreased to 28.0% from 32.8%, primarily due to lower amortization expense from acquisition-related assets, partially offset by higher profit share and manufacturing costs.
Prolia sales fell 32% to $759M and XGEVA fell 34% to $352M, driven by lower volume and net selling price following patent expiries in February 2025 (U.S.) and November 2025 (Europe). Management expects accelerated erosion for the remainder of 2026.
Revenue
$10.05B
+9.53% YoY
EPS (Diluted)
$4.37
+64.91% YoY
Operating Income
$3.51B
+32.30% YoY
Add AMGN to your watchlist to keep its archived reports easy to find. New filing alerts are no longer sent.